Guangzhou Fustop Pharmaceutical

Guangzhou Fustop Pharmaceutical is a China-based biotechnology company focused on the development of innovative therapies for metabolic and chronic diseases. The company specializes in the research and development of small molecule drugs and biologics targeting conditions such as type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). Fustop Pharmaceutical maintains a robust pipeline of candidates, including GLP-1 receptor agonists and SGLT2 inhibitors, aimed at providing more effective treatment options for patients globally. With a strong emphasis on R&D, the company leverages advanced chemical and biological technologies to advance its clinical programs through various stages of development.